132 related articles for article (PubMed ID: 15481917)
1. [Antigenic activity of oral whole-culture meningococcal serogroup B vaccine].
Aleksakhina NN; Basnak'ian IA; Kozlova NN; Verner IK
Zh Mikrobiol Epidemiol Immunobiol; 2004; (4):35-40. PubMed ID: 15481917
[TBL] [Abstract][Full Text] [Related]
2. [Immune response to the oral administration of a new meningococcal preparation, serogroup A, under experiment].
Aleksakhina NN; Basnak'ian IA; Kozlova NN
Zh Mikrobiol Epidemiol Immunobiol; 2004; (3):43-8. PubMed ID: 15346949
[TBL] [Abstract][Full Text] [Related]
3. [Humoral immune response in animals after the oral administration of group C meningococcal whole-culture preparation].
Aleksakhina NN; Basnak'ian IA; Kozlova NN
Zh Mikrobiol Epidemiol Immunobiol; 2004; (5):71-5. PubMed ID: 15554318
[TBL] [Abstract][Full Text] [Related]
4. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
[TBL] [Abstract][Full Text] [Related]
5. [Perspectives for development of polyvalent meningococcal vaccine].
Basnak'ian IA; Aleksakhina NN
Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):54-8. PubMed ID: 17297881
[TBL] [Abstract][Full Text] [Related]
6. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
7. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
Bai X; Borrow R
Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
9. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
Watson PS; Novy PL; Friedland LR
Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
[TBL] [Abstract][Full Text] [Related]
10. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential.
O'dwyer CA; Reddin K; Martin D; Taylor SC; Gorringe AR; Hudson MJ; Brodeur BR; Langford PR; Kroll JS
Infect Immun; 2004 Nov; 72(11):6511-8. PubMed ID: 15501782
[TBL] [Abstract][Full Text] [Related]
11. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
[TBL] [Abstract][Full Text] [Related]
12. New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.
Tamargo B; Márquez Y; Ramírez W; Cedré B; Fresno M; Sierra G
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S12. PubMed ID: 23458443
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
[TBL] [Abstract][Full Text] [Related]
14. [Influence of the growth phase of Neisseria meningitidis on the accumulation of antigens cross-reacting with human antigens in the culture].
Basnak'ian IA; Aleksakhina NN; Iastrebova NE; Vaneeva NP; Kozlova NN
Zh Mikrobiol Epidemiol Immunobiol; 2005; (1):43-9. PubMed ID: 15773399
[TBL] [Abstract][Full Text] [Related]
15. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
17. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
Balmer P; Beeslaar J; Findlow J; Srivastava A
Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.
Afrough P; Bouzari S; Mousavi SF; Asadi Karam MR; Vaziri F; Fateh A; Behrouzi A; Malekan M; Siadat SD
Microb Pathog; 2017 Nov; 112():209-214. PubMed ID: 28942175
[TBL] [Abstract][Full Text] [Related]
19. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
20. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.
Harder T; Koch J; Wichmann O; Hellenbrand W
J Infect; 2017 Aug; 75(2):81-94. PubMed ID: 28487177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
